Haemonetics Corporation (HAE) Gross margin 2017–2026
Haemonetics Corporation (HAE) gross margin by fiscal year — reported gross profit divided by reported revenue.
59.0%FY2026 · since FY2017: 42.7% → 59.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 59.0% | +4.0 pp |
| FY2025 | 55.0% | +2.2 pp |
| FY2024 | 52.8% | +0.2 pp |
| FY2023 | 52.6% | +1.7 pp |
| FY2022 | 50.9% | +5.2 pp |
| FY2021 | 45.7% | -3.3 pp |
| FY2020 | 49.0% | +5.9 pp |
| FY2019 | 43.2% | -2.4 pp |
| FY2018 | 45.6% | +2.9 pp |
| FY2017 | 42.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice